TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
inclusion~Women may be included in the study if they meet all of the following criteria:~* in good general health~* age 18 to 40 years, inclusive~* willing to provide informed consent and follow all study requirements~* not pregnant~* does not desire to become pregnant in the next 24 months~* regular menstrual cycle (24 to 35 days)~* confirmed ovulation by serum P ≥ 4.7 ng/mL in two consecutive samples during the pre-treatment phase of the study~* at low risk of pregnancy (e.g., sterilized, in exclusively same sex partnership, in monogamous relationship with vasectomized partner, abstinent, using non-hormonal IUD or condoms)~* has a body mass index of 18.0 to 35.0~* has hemoglobin ≥10.5 g/L~exclusion~Women will be excluded from participating in this study if they meet any of the following criteria:~* medical contraindications to DMPA use~* use of any of the following medications within 1 month prior to enrollment:~  * any investigational drug~ * prohibited drugs (per protocol)~ * oral contraceptives~ * LNG IUS or implant~* use of DMPA in the past 12 months~* use of a combined injectable contraceptive in the past 6 months~* recent pregnancy (within 3 months)~* current lactation~* ongoing or anticipated use of prohibited drugs (per protocol)~* known sensitivity to MPA~* plan to move to another location in the next 18 months~* any condition (social or medical) which in the opinion of the site investigator would make study participation unsafe, would interfere with adherence to study requirements or complicate data interpretation.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- DMPA 150 (Type: EXPERIMENTAL): single subcutaneous injection of 150mg/mL of DMPA in the abdomen
- DMPA 300 (Type: EXPERIMENTAL): single subcutaneous injection of 300mg/2mL of DMPA in the abdomen
- DMPA 104 (Type: ACTIVE_COMPARATOR): two injections, given at three months intervals, of 104mg/0.65mL of DMPA in the abdomen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Extension of a Clinical Trial of Intravitreal Triamcinolone for Diabetic Macular Oedema-TDMX Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Participation in the study will be offered to all patients at the conclusion of the TDMO study. Currently we are still following 64 of the 69 (93%) eyes that were initially entered into the study that had reduced vision from diabetic macular oedema at baseline.~Exclusion Criteria:~* Uncontrolled glaucoma~* Loss of vision due to other causes (e.g. age related macular degeneration, myopic macular degeneration)~* known allergies to triamcinolone acetate, patient is already receiving systemic steroid treatment, intercurrent severe disease such as septicemia, any condition which would affect follow-up or photographic documentation (e.g. geographical, psycho-social, media opacities)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Bilateral ROP in zone I (stage 1+, 2+, 3+/-, AP-ROP) or ROP in central (=posterior) zone II (stage 3+, AP-ROP). Zone I is defined as twice the distance from the optic disc to the fovea measured temporally, posterior zone II is defined as three times the distance from the optic disc to the fovea measured temporally.~* Legal representatives or their designates willing and able to attend regular study visits with the study infant.~* Written informed consent to participate in the study (signed by all patient's legal representatives).~Exclusion Criteria:~* Pediatric conditions rendering the infant ineligible to anti-VEGF treatment or to repeated blood draws as evaluated by a neonatal ICU specialist and a study ophthalmologist.~* Congenital brain lesions significantly impairing optic nerve function.~* Severe hydrocephalus with significantly increased intracranial pressure.~* Advanced stages of ROP with partial or complete retinal detachment (ROP stage 4 and 5).~* ROP involving only the peripheral retina (i.e. peripheral zone II or zone III).~* Known hypersensitivity to the study drug or to drugs with similar chemical structures.~* Contraindications for an intravitreal injection as listed in ranibizumab SmPC.~* Systemic use of anti-VEGF therapeutics.~* Use of other investigational drugs - excluding vitamins and minerals - at the time of enrollment, or within 30 days or 5 half-lives prior to enrollment, whichever is longer.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab 0.12 mg (Type: EXPERIMENTAL): 20 µl of the 6 mg/ml ranibizumab concentration will be applied intravitreally. After an initial response the same dose as in the first injection can be re-applied after at least four weeks post injection.~A maximum number of 3 regular re-injections can be applied.
- Ranibizumab 0.20 mg (Type: EXPERIMENTAL): 20 µl of the 10 mg/ml ranibizumab concentration will be applied intravitreally. After an initial response the same dose as in the first injection can be re-applied after at least four weeks post injection.~A maximum number of 3 re-injections can be applied.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, 18-65 years old~* Experienced a Major Depressive Disorder with the current episode of minimally 8 weeks in duration.~* Treatment history of an inadequate response to at least one and no more than three antidepressants.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A1 (Type: PLACEBO_COMPARATOR): None
- A2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prediction of Delivery With Transperineal Ultrasound in Women With Prolonged Labour. Multicentre Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Primiparous women with single pregnancies and gestation age \> 37 weeks and prolonged first stage of labor~Exclusion Criteria:~* High risk pregnancies,~* premature deliveries,~* multiple pregnancies

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 48 Years
- Healthy Volunteers: t

Study Arms:
- ultrasound (Type: None): primiparous women with prolonged labours will be eligible for examination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Does Alkalinization Reduce Perceived Pain Levels During Sentinel Lymph Node Imaging?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting for SLN imaging for melanoma or who have had an excisional biopsy for melanoma of the thorax and appendicular structures;~* Patients scheduled to receive two or more injections of Tc-99m SC for the purpose of clinical management of melanoma or who have had an excisional biopsy for melanoma of the thorax and appendicular structures.~Exclusion Criteria:~* Patients presenting for SLN imaging of lesions involving the breast, ear, nose, and genitourinary regions;~* Patients scheduled to receive only a single injection of Tc-99m SC;~* Pregnant or breast feeding women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 122 Years
- Healthy Volunteers: f

Study Arms:
- pH altered first (Type: ACTIVE_COMPARATOR): The first injection administered will be the pH altered solution. The second injection will be the standard of care solution (opposite order). The remaining injections will be randomly assigned as either standard of care or pH altered.
- Standard of Care first (Type: ACTIVE_COMPARATOR): The first injection administered will be the standard of care solution (SOC). The second injection will be the pH altered solution. The remaining injections will be randomly assigned as either standard of care or pH altered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Spontaneous intracerebral hemorrhage as documented by head CT scan~* Documented regular aspirin use or VerifyNow-ASA result of ≤ 550 aspirin reaction units (ARU), indicating anti-platelet medication~Exclusion Criteria:~* International normalized ratio (INR) of ≥ 1.7 from coagulopathy or warfarin use~* History of von Willebrand disease~* Pregnancy~* Known hypersensitivity to DDAVP or desmopressin~* Active cardiovascular disease or unstable angina~* Hyponatremia or history of hyponatremia~* Current or historical deep venous thrombosis or pulmonary embolism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- DDAVP (Type: EXPERIMENTAL): DDAVP 0.4 mcg/kg intravenously in 250 mL NS over 30 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparative Effectiveness Trial of Optimal Patient-Centered Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Seen in acute care emergency department or trauma center setting for injury~* At least three post traumatic concerns~* AND One of the following PTSD Checklist Score (PCL-C) greater than or equal to 35 Patient Health Questionnaire 9 - greater than or equal to 10 Any endorsement of suicidal ideation on the PhQ-9 Item 9~Exclusion Criteria:~* Non-English speaking~* Under 14 years of age~* Incarcerated~* Psychotic behavior~* Suffered head, spinal cord, or other severe injuries that prevent participation in the inpatient ward interview.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enhanced Usual Care - Nurse Notification of Patient Concerns (Type: NO_INTERVENTION): Randomized and will be blindly assessed.
- Patient-centered care transition (Type: EXPERIMENTAL): Case management, information technology/mHealth innovations, stepped-up psychopharmacology and psychotherapy elements.~Randomized and will be blindly assessed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metformin Reduce the Relapse Rate on Patients With B-cell Precursor (Ph+ Negative) Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years~* de novo B-cell precursor Acute Lymphoblastic Leukemia~* candidates to first line treatment protocol~* ECOG (Eastern Cooperative Oncology Group) Scale of Performance Status 1/2~* Informed Consent Form for genetic analysis samples~* Precursor B Cell Acute Lymphoblastic Leukemia~Exclusion Criteria:~* Diagnose of Acute Myelogenous Leukemia or Biphenotype Leukemia~* Diagnose of type 2 Diabetes Mellitus~* Previous use of Metformin~* Relapsed Acute Leukemia that require treatment protocol to be started~* Intolerance to prednisone~* ECOG Scale of Performance Status 3/4~* T-cell Acute Lymphoblastic Leukemia~* Philadelphia positive Acute Lymphoblastic Leukemia~* Tumor lysis syndrome at diagnose~* Renal Failure (creatinine leve higher than 2mg/dl)~* Several liver damage (\>2 levels de upper normal limit of Aspartate transaminase (AST) and alanine transaminase (ALT)~* Metabolic Acidosis or Lactic Acidosis at diagnose~* Central nervous system infiltration at diagnose~* Extramedullary disease (skin, pleura,eye)~* Active GI bleeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- metformin (Type: ACTIVE_COMPARATOR): Metformin 850mg PO three times a day, during the pre-induction with steroids, induction remission, consolidation and maintenance
- No metformin (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: High Dose Vitamin D for Sickle Cell Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* all sickle cell genotypes including SS, SB0thal, SC, SB+Thal~* Age 7-21 years old~* Last PRBC transfusion \>30 days prior~Exclusion Criteria:~* chronic renal failure~* chronic liver disease~* recent hospitalization \<14 days~* history of malignancy~* serum calcium level as defined in protocol section D 2.2~* treatment with concommitant medications as defined in section D 2.2 of the protocol~* known malabsorption or short gut syndrome or conditions associated with poor GI absorption~* patients currently on high dose vitamin D therapy

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Vitamin D (Type: ACTIVE_COMPARATOR): 10,000 IU per caplet, with vitamin D dose based on weight, ranging from 240,000 IU to 600,000 IU. Patients will receive calcium/vitamin D daily soft chew as well.
- Placebo (Type: PLACEBO_COMPARATOR): placebo only, all patients will receive calcium/vitamin D chew

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Does Outpatient Palliative Care Improve Patient-centered Outcomes in Parkinson's Disease?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fluent in English~* UK Brain Bank criteria for diagnosis of probable PD or Multiple Systems Atrophy (MSA) or Corticobasal Degeneration (CBD) or Progressive Supranuclear Palsy (PSP) or Lewy Body Dementia (LBD)~* At high risk for poor outcomes as identified by the Palliative Care Needs Assessment Tool (PC-NAT)~Exclusion Criteria:~* Immediate and urgent palliative care needs~* Unable or unwilling to commit to study procedures including;~  1. randomization,~ 2. study visits or~ 3. the addition of a neurologist to their care team~* Presence of additional chronic medical illnesses which may require palliative services~* Already receiving palliative care and/or hospice services.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: OTHER): Usual care as in including both a Primary Care Physician (PCP) and neurologist.
- Interdisciplinary outpatient palliative care (Type: ACTIVE_COMPARATOR): Usual care augmented by an outpatient interdisciplinary palliative care team.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients suffering and diagnosed for: metastatic cancer of several entities~* Clinical indicated therapy with PD-1/PD-L1 inhibitors or CTLA-4 antagonists~* Optionally radiotherapy if clinically indicated~* Age at least 18 years~Exclusion Criteria:~* fertile patients who refuse effective contraception during study treatment~* persistent drug and/or alcohol abuse~* patients not able or willing to behave according to study protocol~* patients in care~* patients that are not able to speak German~* patients which are imprisoned according to legal or governmental order

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- anti CTLA-4 (Type: None): The study cohort consist of patients suffering from metastatic cancer of several entities which will be treated with palliative RT and/or ICI (anti CTLA-4) at Department of Radiation Oncology of Universitätsklinikum Erlangen.
- anti PD-1/PD-L1 (Type: None): The study cohort consist of patients suffering from metastatic cancer of several entities which will be treated with palliative RT and/or ICI (anti PD-1/PD-L1) at Department of Radiation Oncology of Universitätsklinikum Erlangen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Social Media And Risk-reduction Training for Infant Care Practices (SMART)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~- mothers must live in the US, deliver a healthy infant in one of the study hospitals, plan to take her baby home with her, and be able to receive emails.~Exclusion Criteria:~- mothers who are not English speaking, whose infant is deceased, those not having custody of the infant, and those whose infants require hospitalization for more than 1 week, or have an ongoing medical problem requiring subspecialty care and mothers who are unable to receive email messages.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Safe Sleep Edu and Breastfeeding mHealth (Type: OTHER): Participants will receive Safe Sleep Nursery Education and Breastfeeding Mobile Health messaging
- Breastfeeding Edu and Safe Sleep mHealth (Type: OTHER): Participants will receive the Breastfeeding Nursery Education and the Safe Sleep Mobile Health messaging
- Safe Sleep Edu and Safe Sleep mHealth (Type: OTHER): Participants will receive Safe Sleep Nursery Education and Safe Sleep Mobile Health messaging
- Breastfeed Edu and Breastfeed mHealth (Type: OTHER): Participants will receive Breastfeeding Nursery Education and Breastfeeding Mobile Health messaging

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 10.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed acute lymphoblastic leukemia (ALL)~* No secondary ALL~PATIENT CHARACTERISTICS:~* No prior disease that would preclude treatment with chemotherapy~PRIOR CONCURRENT THERAPY:~* More than 4 weeks since prior chemotherapy~* More than 4 weeks since prior steroids

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Induction Prot I/Dexa - reinduction Prot III (Type: EXPERIMENTAL): None
- Induction Prot I/Pred - reinduction Prot III (Type: EXPERIMENTAL): None
- Induction Prot I/Dexa - reinduction Prot II (Type: EXPERIMENTAL): None
- Induction Prot I/Pred - reinduction Prot II (Type: ACTIVE_COMPARATOR): None
- Induction Prot I/Dexa - reinduction 2x Prot III (Type: EXPERIMENTAL): None
- Induction Prot I/Pred - reinduction 2x Prot III (Type: EXPERIMENTAL): None
- Induction Prot I/Dexa - reinduction 3 HR courses + 3x Prot III (Type: EXPERIMENTAL): None
- Induction Prot I/Pred - reinduction 3 HR courses + 3x Prot III (Type: EXPERIMENTAL): None
- Induction Prot I/Dexa - reinduction 6 HR courses + Prot II (Type: EXPERIMENTAL): None
- Induction Prot I/Pred - reinduction 6 HR courses + Prot II (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete